New Pyrazolyl-substituted Heteroaryls and their use as Medicaments
US-2017073333-A1 · Mar 16, 2017 · US
Heteroaryl Syk inhibitors
US9914735B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9914735-B2 |
| Application number | US-201515027518-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 12, 2015 |
| Priority date | Mar 19, 2014 |
| Publication date | Mar 13, 2018 |
| Grant date | Mar 13, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to new substituted heteroaryls of formula (1), wherein A is selected from the group consisting of N and CH, D is CH, E is selected from the group consisting of C and N, T is C, G is selected from the group consisting of C and N, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all single and double bonds of ring 1 are arranged in such a way that they all form together with ring 2 an aromatic ring system, and wherein R 1 , M and R 3 are defined according to claim 1 , and to the above compounds for the treatment of a disease selected from the group consisting of asthma, COPD, allergic rhinitis, allergic dermatitis, lupus erythematodes, lupus nephritis and rheumatoid arthritis.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound, which is or a pharmaceutically acceptable salt thereof. 2. A compound, which is or a pharmaceutically acceptable salt thereof. 3. A method of treating asthma comprising the step of administering to a person in need thereof the compound according to claim 1 or a pharmaceutically acceptable salt thereof. 4. A method of treating COPD comprising the step of administering to a person in need thereof the compound according to claim 1 or a pharmaceutically acceptable salt thereof. 5. A pharmaceutical formulation comprising the compound according to claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 6. A pharmaceutical formulation comprising the compound according to claim 2 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. 7. A method of treating asthma comprising the step of administering to a person in need thereof the compound according to claim 2 or a pharmaceutically acceptable salt thereof. 8. A method of treating COPD comprising the step of administering to a person in need thereof the compound according to claim 2 or a pharmaceutically acceptable salt thereof. 9. A pharmaceutical formulation comprising the compound according to claim 1 , or a pharmaceutically acceptable salt thereof, in combination with an active substance selected from the group consisting of anticholinergics, betamimetics, corticosteroids, PDE4-inhibitors, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, CRTH2-antagonists, HMG-CoA reductase inhibitors and NSAIDs. 10. A pharmaceutical formulation comprising the compound according to claim 2 , or a pharmaceutically acceptable salt thereof, in combination with an active substance selected from the group consisting of anticholinergics, betamimetics, corticosteroids, PDE4-inhibitors, EGFR-inhibitors, LTD4-antagonists, CCR3-inhibitors, iNOS-inhibitors, CRTH2-antagonists, HMG-CoA reductase inhibitors and NSAIDs.
Assignees
Inventors
Classifications
Drugs for disorders of the cardiovascular system · CPC title
Drugs for disorders of the blood or the extracellular fluid · CPC title
Antioedematous agents; Diuretics · CPC title
Drugs for immunological or allergic disorders · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9914735B2 cover?
- The invention relates to new substituted heteroaryls of formula (1), wherein A is selected from the group consisting of N and CH, D is CH, E is selected from the group consisting of C and N, T is C, G is selected from the group consisting of C and N, and wherein each of the broken (dotted) double bonds in ring 1 are selected from either a single bond or a double bond under the proviso that all …
- Who is the assignee on this patent?
- Boehringer Ingelheim Int
- What technology area does this patent fall under?
- Primary CPC classification C07D487/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 4 related publications on this page (citations in our corpus or others sharing the same primary CPC).